Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

80% Valley Polarization of Free Carriers in Singly Oriented Single-Layer WS_{2} on Au(111).

Beyer H, Rohde G, Grubišić Čabo A, Stange A, Jacobsen T, Bignardi L, Lizzit D, Lacovig P, Sanders CE, Lizzit S, Rossnagel K, Hofmann P, Bauer M.

Phys Rev Lett. 2019 Dec 6;123(23):236802. doi: 10.1103/PhysRevLett.123.236802.

PMID:
31868459
2.

Extreme angle, tip-tilt MEMS micromirror enabling full hemispheric, quasi-static optical coverage.

Pollock C, Javor J, Stange A, Barrett LK, Bishop DJ.

Opt Express. 2019 May 27;27(11):15318-15326. doi: 10.1364/OE.27.015318.

PMID:
31163729
3.

Building a Casimir metrology platform with a commercial MEMS sensor.

Stange A, Imboden M, Javor J, Barrett LK, Bishop DJ.

Microsyst Nanoeng. 2019 Apr 22;5:14. doi: 10.1038/s41378-019-0054-5. eCollection 2019.

4.

Ultrafast Formation of a Fermi-Dirac Distributed Electron Gas.

Rohde G, Stange A, Müller A, Behrendt M, Oloff LP, Hanff K, Albert TJ, Hein P, Rossnagel K, Bauer M.

Phys Rev Lett. 2018 Dec 21;121(25):256401. doi: 10.1103/PhysRevLett.121.256401.

PMID:
30608821
5.

Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial.

Berger AK, Lücke S, Abel U, Haag GM, Grüllich C, Stange A, Dietrich M, Apostolidis L, Freitag A, Trierweiler C, von Gall C, Ose J, Giesel F, Weber TF, Lordick F, Haberkorn U, Jäger D.

Br J Cancer. 2018 Jul;119(2):170-175. doi: 10.1038/s41416-018-0152-4. Epub 2018 Jul 2.

6.

Clinical and laboratory factors contributing to uninterpretable beryllium lymphocyte proliferation tests (BeLPT).

Smith DE, Golden AP, Stange AW, Barker E, Mroz M, Barón AE, Ghosh D, Maier L, Cragle D, Newman LS.

Am J Ind Med. 2018 Jul;61(7):592-604. doi: 10.1002/ajim.22842. Epub 2018 Mar 24.

7.

Time-resolved ARPES with sub-15 fs temporal and near Fourier-limited spectral resolution.

Rohde G, Hendel A, Stange A, Hanff K, Oloff LP, Yang LX, Rossnagel K, Bauer M.

Rev Sci Instrum. 2016 Oct;87(10):103102.

PMID:
27802702
8.

Self-amplified photo-induced gap quenching in a correlated electron material.

Mathias S, Eich S, Urbancic J, Michael S, Carr AV, Emmerich S, Stange A, Popmintchev T, Rohwer T, Wiesenmayer M, Ruffing A, Jakobs S, Hellmann S, Matyba P, Chen C, Kipp L, Bauer M, Kapteyn HC, Schneider HC, Rossnagel K, Murnane MM, Aeschlimann M.

Nat Commun. 2016 Oct 4;7:12902. doi: 10.1038/ncomms12902.

9.

Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma.

Springfeld C, Wiecha C, Kunzmann R, Heger U, Weichert W, Langer R, Stange A, Blank S, Sisic L, Schmidt T, Lordick F, Jäger D, Grenacher L, Bruckner T, Büchler MW, Ott K.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S905-14. doi: 10.1245/s10434-015-4617-x. Epub 2015 May 22.

PMID:
26001861
10.

How fast can a Peierls-Mott insulator be melted?

Sohrt C, Stange A, Bauer M, Rossnagel K.

Faraday Discuss. 2014;171:243-57. doi: 10.1039/c4fd00042k. Epub 2014 Aug 7.

PMID:
25415852
11.

Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation.

Blank S, Lordick F, Bader F, Burian M, Dobritz M, Grenacher L, Becker K, Weichert W, Langer R, Sisic L, Stange A, Jäger D, Büchler M, Bruckner T, Siewert J, Ott K.

Gastric Cancer. 2015 Apr;18(2):314-25. doi: 10.1007/s10120-014-0367-x. Epub 2014 Apr 11.

PMID:
24722800
12.

Emphasis of spatial cues in the temporal fine structure during the rising segments of amplitude-modulated sounds II: single-neuron recordings.

Dietz M, Marquardt T, Stange A, Pecka M, Grothe B, McAlpine D.

J Neurophysiol. 2014 May;111(10):1973-85. doi: 10.1152/jn.00681.2013. Epub 2014 Feb 19.

13.

Adaptation in sound localization: from GABA(B) receptor-mediated synaptic modulation to perception.

Stange A, Myoga MH, Lingner A, Ford MC, Alexandrova O, Felmy F, Pecka M, Siveke I, Grothe B.

Nat Neurosci. 2013 Dec;16(12):1840-7. doi: 10.1038/nn.3548. Epub 2013 Oct 20.

PMID:
24141311
14.

An N-terminal domain helical motif of Prototype Foamy Virus Gag with dual functions essential for particle egress and viral infectivity.

Reh J, Stange A, Götz A, Rönitz M, Große A, Lindemann D.

Retrovirology. 2013 Apr 25;10:45. doi: 10.1186/1742-4690-10-45.

15.

Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction.

Weber MA, Bender K, von Gall CC, Stange A, Grünberg K, Ott K, Haberkorn U, Kauczor HU, Zechmann C.

J Gastrointestin Liver Dis. 2013 Mar;22(1):45-52.

16.

A reliable risk score for stage IV esophagogastric cancer.

Blank S, Lordick F, Dobritz M, Grenacher L, Burian M, Langer R, Roth W, Schaible A, Becker K, Bläker H, Sisic L, Stange A, Compani P, Schulze-Bergkamen H, Jäger D, Büchler M, Siewert JR, Ott K.

Eur J Surg Oncol. 2013 Aug;39(8):823-30. doi: 10.1016/j.ejso.2013.01.005. Epub 2013 Jan 31.

PMID:
23375470
17.

Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor.

Ott K, Blank S, Becker K, Langer R, Weichert W, Roth W, Sisic L, Stange A, Jäger D, Büchler M, Siewert JR, Lordick F.

Langenbecks Arch Surg. 2013 Feb;398(2):239-49. doi: 10.1007/s00423-012-1039-0. Epub 2012 Dec 27.

PMID:
23269519
18.

Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients.

Blank S, Stange A, Sisic L, Roth W, Grenacher L, Sterzing F, Burian M, Jäger D, Büchler M, Ott K.

Langenbecks Arch Surg. 2013 Feb;398(2):211-20. doi: 10.1007/s00423-012-1034-5. Epub 2012 Dec 7.

PMID:
23224565
19.

Time-domain classification of charge-density-wave insulators.

Hellmann S, Rohwer T, Kalläne M, Hanff K, Sohrt C, Stange A, Carr A, Murnane MM, Kapteyn HC, Kipp L, Bauer M, Rossnagel K.

Nat Commun. 2012;3:1069. doi: 10.1038/ncomms2078.

PMID:
22990865
20.

Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS--a randomised controlled multicentre trial (ISRCTN30964555).

Rahbari NN, Lordick F, Fink C, Bork U, Stange A, Jäger D, Luntz SP, Englert S, Rossion I, Koch M, Büchler MW, Kieser M, Weitz J; SYNCHRONOUS trial group.

BMC Cancer. 2012 Apr 5;12:142. doi: 10.1186/1471-2407-12-142.

21.

A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial.

Berger AK, von Gall C, Abel U, Delorme S, Kloor M, Ose J, Weber TF, Stange A, Haag GM, Haberkorn U, Lordick F, Jäger D.

BMC Cancer. 2012 Mar 22;12:108. doi: 10.1186/1471-2407-12-108.

22.

A special pair of phytohormones controls excitability, slow closure, and external stomach formation in the Venus flytrap.

Escalante-Pérez M, Krol E, Stange A, Geiger D, Al-Rasheid KA, Hause B, Neher E, Hedrich R.

Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15492-7. doi: 10.1073/pnas.1112535108. Epub 2011 Sep 6.

23.

Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.

Lorenzen S, von Gall C, Stange A, Haag GM, Weitz J, Haberkorn U, Lordick F, Weichert W, Abel U, Debus J, Jäger D, Münter MW.

BMC Cancer. 2011 Jun 24;11:266. doi: 10.1186/1471-2407-11-266.

24.

Collapse of long-range charge order tracked by time-resolved photoemission at high momenta.

Rohwer T, Hellmann S, Wiesenmayer M, Sohrt C, Stange A, Slomski B, Carr A, Liu Y, Avila LM, Kalläne M, Mathias S, Kipp L, Rossnagel K, Bauer M.

Nature. 2011 Mar 24;471(7339):490-3. doi: 10.1038/nature09829. Epub 2011 Mar 9.

PMID:
21389987
25.

Analysis of prototype foamy virus particle-host cell interaction with autofluorescent retroviral particles.

Stirnnagel K, Lüftenegger D, Stange A, Swiersy A, Müllers E, Reh J, Stanke N, Grosse A, Chiantia S, Keller H, Schwille P, Hanenberg H, Zentgraf H, Lindemann D.

Retrovirology. 2010 May 17;7:45. doi: 10.1186/1742-4690-7-45.

26.

Ca(2+)-dependent activation of guard cell anion channels, triggered by hyperpolarization, is promoted by prolonged depolarization.

Stange A, Hedrich R, Roelfsema MR.

Plant J. 2010 Apr;62(2):265-76. doi: 10.1111/j.1365-313X.2010.04141.x. Epub 2010 Jan 19.

27.

Activity of guard cell anion channel SLAC1 is controlled by drought-stress signaling kinase-phosphatase pair.

Geiger D, Scherzer S, Mumm P, Stange A, Marten I, Bauer H, Ache P, Matschi S, Liese A, Al-Rasheid KA, Romeis T, Hedrich R.

Proc Natl Acad Sci U S A. 2009 Dec 15;106(50):21425-30. doi: 10.1073/pnas.0912021106. Epub 2009 Dec 2.

28.

Subviral particle release determinants of prototype foamy virus.

Stange A, Lüftenegger D, Reh J, Weissenhorn W, Lindemann D.

J Virol. 2008 Oct;82(20):9858-69. doi: 10.1128/JVI.00949-08. Epub 2008 Aug 6.

29.
30.

Ubiquitination of the prototype foamy virus envelope glycoprotein leader peptide regulates subviral particle release.

Stanke N, Stange A, Lüftenegger D, Zentgraf H, Lindemann D.

J Virol. 2005 Dec;79(24):15074-83.

31.

Characterization of prototype foamy virus gag late assembly domain motifs and their role in particle egress and infectivity.

Stange A, Mannigel I, Peters K, Heinkelein M, Stanke N, Cartellieri M, Göttlinger H, Rethwilm A, Zentgraf H, Lindemann D.

J Virol. 2005 May;79(9):5466-76.

32.

Positive affectivity and lifestyle in adulthood: do you do what you feel?

Kunzmann U, Stange A, Jordan J.

Pers Soc Psychol Bull. 2005 Apr;31(4):574-88.

PMID:
15743990
33.

Prototype foamy virus envelope glycoprotein leader peptide processing is mediated by a furin-like cellular protease, but cleavage is not essential for viral infectivity.

Duda A, Stange A, Lüftenegger D, Stanke N, Westphal D, Pietschmann T, Eastman SW, Linial ML, Rethwilm A, Lindemann D.

J Virol. 2004 Dec;78(24):13865-70.

34.

The beryllium lymphocyte proliferation test: Relevant issues in beryllium health surveillance.

Stange AW, Furman FJ, Hilmas DE.

Am J Ind Med. 2004 Nov;46(5):453-62.

PMID:
15490468
35.

Beryllium sensitization and chronic beryllium disease at a former nuclear weapons facility.

Stange AW, Hilmas DE, Furman FJ, Gatliffe TR.

Appl Occup Environ Hyg. 2001 Mar;16(3):405-17.

PMID:
11297055
36.

A Coordination-Induced 1,4→1,2-Quinonediimine Isomerization.

Rall J, Stange AF, Hübler K, Kaim W.

Angew Chem Int Ed Engl. 1998 Oct 16;37(19):2681-2682. doi: 10.1002/(SICI)1521-3773(19981016)37:19<2681::AID-ANIE2681>3.0.CO;2-9.

PMID:
29711603
37.

Rocky Flats Beryllium Health Surveillance.

Stange AW, Furman FJ, Hilmas DE.

Environ Health Perspect. 1996 Oct;104 Suppl 5:981-6.

38.

Possible health risks from low level exposure to beryllium.

Stange AW, Hilmas DE, Furman FJ.

Toxicology. 1996 Jul 17;111(1-3):213-24.

PMID:
8711738
40.

CpIr(dab) (dab = 1,4-Bis(2,6-dimethylphenyl)-1,4-diazabutadiene): A Coordinatively Unsaturated Six-pi-Electron Metallaheteroaromatic Compound?

Greulich S, Kaim W, Stange AF, Stoll H, Fiedler J, Zális S.

Inorg Chem. 1996 Jun 19;35(13):3998-4002.

PMID:
11666595
41.

Associated production of Higgs and weak bosons, with H-->bb-bar, at hadron colliders.

Stange A, Marciano W, Willenbrock S.

Phys Rev D Part Fields. 1994 Oct 1;50(7):4491-4498. No abstract available.

PMID:
10018088
42.

Higgs bosons at the Fermilab Tevatron.

Stange A, Marciano W, Willenbrock S.

Phys Rev D Part Fields. 1994 Feb 1;49(3):1354-1362. No abstract available.

PMID:
10017107
43.

Yukawa correction to top-quark production at the Fermilab Tevatron.

Stange A, Willenbrock S.

Phys Rev D Part Fields. 1993 Sep 1;48(5):2054-2061. No abstract available.

PMID:
10016442
44.

What e+e- collider could make a "no-lose" search for minimum supersymmetric standard model Higgs bosons?

Barger V V, Cheung K, Phillips RJ, Stange AL.

Phys Rev D Part Fields. 1993 Apr 1;47(7):3041-3044. No abstract available.

PMID:
10015909
45.

Collider discovery limits for supersymmetric Higgs bosons.

Barger V V, Cheung K, Phillips RJ, Stange AL.

Phys Rev D Part Fields. 1992 Dec 1;46(11):4914-4929. No abstract available.

PMID:
10014873
46.

Full tree-level calculation of the qq-->qqWZ electroweak process at hadron supercolliders.

Barger V V, Cheung K, Han T, Stange A, Zeppenfeld D.

Phys Rev D Part Fields. 1992 Sep 1;46(5):2028-2039. No abstract available.

PMID:
10015118
47.

Supersymmetric-Higgs-boson hadroproduction and decays including radiative corrections.

Barger V V, Berger MS, Stange AL, Phillips RJ.

Phys Rev D Part Fields. 1992 Jun 1;45(11):4128-4147. No abstract available.

PMID:
10014319
48.

Numerical evaluation of color factors.

Barger V V, Stange AL, Phillips RJ.

Phys Rev D Part Fields. 1992 Mar 1;45(5):1751-1753. No abstract available.

PMID:
10014546
49.

Multiple-weak-boson signals at hadron supercolliders.

Barger V V, Stange AL, Phillips RJ.

Phys Rev D Part Fields. 1992 Mar 1;45(5):1484-1502. No abstract available.

PMID:
10014521
50.

Four-heavy-quark hadroproduction.

Barger V V, Stange AL, Phillips RJ.

Phys Rev D Part Fields. 1991 Oct 1;44(7):1987-1996. No abstract available.

PMID:
10014078

Supplemental Content

Loading ...
Support Center